by ComplianceQuest

Inspection Tracker

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

FDA Guidance Global Templates

Start with a Free ConsultationBook 30 minutes with a ComplianceQuest specialist.Book a Call

Sign In Create a Free Account

Big News: FDA is moving from MasterControl to ComplianceQuest.See Why

Search AgentQ/

Talk to a Specialist

Loading…

My DashboardInspection TrackerWarning LettersBeaute Bounty

All Warning Letters

Beaute Bounty

Warning LetterOpen

Beautebounty@gmail.comIssued Sep 25, 2026Center for Biologics Evaluation and Research (CBER)

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations4

Issue DateSep 25, 2026

Product TypeBiologics

StatusOpen

Letter Details

Firm: Beaute Bounty
Location: Beautebounty@gmail.com
FEI Number: N/A
Country: Malaysia
Issue Date: September 25, 2026
Issuing Office: Center for Biologics Evaluation and Research (CBER)
Product Type: Biologics
Status: Open

Subject

Unapproved New Drugs/Unlicensed Biological Product Violations

Beaute Bounty FDA Warning Letter, September 25, 2026